Katsuyuki Kiura
Okayama University
CancerInternal medicineSurgeryPathologyOncologyLung cancerChemotherapyCarcinomaLungT790MCisplatinEpidermal growth factor receptorGefitinibAdenocarcinomaDocetaxelNon small cellCancer researchMedicineBiologyGastroenterology
680Publications
68H-index
12kCitations
Publications 678
Newest
#1Eri Ando (Okayama University)
#2Takamasa Nakasuka (Okayama University)H-Index: 4
Last. Katsuyuki Hotta (Okayama University)H-Index: 39
view all 15 authors...
A 16-year-old boy with asthma participated in recovery volunteer work following the 2018 heavy rains in Japan. One month later, he experienced chest pain and dyspnea. Chest computed tomography revealed a cavity with a fungal ball, and Aspergillus fumigatus was detected in his bronchoalveolar lavage fluid. He was treated with voriconazole, but new consolidations appeared rapidly. He also experienced allergic bronchopulmonary aspergillosis. After prednisolone prescription, the consolidations impro...
Source
#1Takashi Ninomiya (Okayama University)H-Index: 13
#2Naoyuki Nogami (Ehime University)
Last. Akihiro BesshoH-Index: 17
view all 20 authors...
Background null In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer. Herein, we report the 2-year progression-free survival, overall survival and safety profile of these patients. null Methods null Chemo-naive patients with EGFR-mutant advanced non-small-cell lung cancer were enrolled. One group of patients rec...
Source
#1Kuniaki Katsui (Okayama University)H-Index: 12
#2Takeshi OgataH-Index: 4
Last. Susumu Kanazawa (Okayama University)H-Index: 38
view all 10 authors...
Source
#1Kazuya Nishii (Okayama University)H-Index: 5
#2Kadoaki Ohashi (Okayama University)H-Index: 20
Last. Kammei Rai (Okayama University)H-Index: 6
view all 15 authors...
Source
#1Junichi Soh (Okayama University)H-Index: 35
#2Seiichiro Sugimoto (Okayama University)H-Index: 16
Last. Shinichi Toyooka (Okayama University)H-Index: 72
view all 15 authors...
Abstract Background Trimodality therapy is a treatment option for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Thoracic radiation has both early (radiation pneumonitis) and late (chronic lung injury: CLI) adverse effects on the lung. While CLI is expected to result in various problems in long-term survivors, these manifestations have not been precisely investigated. Methods We enrolled 112 LA-NSCLC patients who had received induction chemoradiotherapy followed by surgery...
1 CitationsSource
#1Eiki IchiharaH-Index: 21
#2Hiroyuki YasudaH-Index: 22
Last. Azusa TanimotoH-Index: 12
view all 16 authors...
Source
#1Hirohisa Kano (Okayama University)H-Index: 4
#2Eiki Ichihara (Okayama University)H-Index: 21
Last. Kammei Rai (Okayama University)H-Index: 6
view all 15 authors...
After molecular-targeted therapy, some cancer cells may remain that are resistant to therapies targeting oncogene alterations, such as those in the genes encoding the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) as well as c-ros oncogene 1 (ROS1). The mechanisms underlying this type of resistance are unknown. Here we report the potential role of Src homology 2 domain-containing phosphatase 2 (SHP2) in the residual cells of ALK/ROS1/EGFR-altered non-small-cell lung...
Source
#1Kuniaki Katsui (Okayama University)H-Index: 12
#2Takeshi OgataH-Index: 4
Last. Susumu Kanazawa (Okayama University)H-Index: 38
view all 10 authors...
We intended to investigate whether muscle and adipose masses were associated with prognosis among patients with stage III non-small-cell lung cancer (NSCLC) who were undergoing chemoradiotherapy (CCRT). We retrospectively explored data of patients with stage III NSCLC who underwent definitive CCRT (≥ 60 Gy) between January 2004 and March 2018 at our hospital. We examined the relationship of overall survival (OS) with body mass index (BMI), skeletal muscle index (SMI), psoas muscle index (PMI), v...
Source
#1Kazuto Nishio (Kindai University)H-Index: 86
#2Takashi SetoH-Index: 52
Last. Kazuhiko Nakagawa (Kindai University)H-Index: 97
view all 22 authors...
ABSTRACT Introduction The phase 3 RELAY global study (NCT02411448) showed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM+ERL) compared with placebo plus erlotinib (PL+ERL) in untreated EGFR-mutated metastatic non-small cell lung cancer. This prespecified analysis evaluates efficacy, safety, and post-progression EGFR T790M rates of RELAY patients enrolled in Japan. Methods Patients were randomized (1:1) to oral erlotinib (150 mg/day) plus intraveno...
Source
#1Sakae Arimoto-Kobayashi (Okayama University)H-Index: 14
#2Kensuke Sasaki (Okayama University)
Last. Katsuyuki Kiura (Okayama University)H-Index: 68
view all 10 authors...
Previously, we isolated and identified anti-mutagenic and anti-inflammatory components from Vitis coignetiae (crimson glory vine, known as yamabudo in Japan) as 2,6-dimethoxy-1,4-benzoquinone (DBQ), fertaric acid and caftaric acid. We also reported that the oral intake of a partially purified fraction from yamabudo juice (yamabudo-fr) or DBQ affords significant protection against two-stage skin carcinogenesis in mice. In this study, we found that oral intake of yamabudo-fr or DBQ affords signifi...
Source